Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial

[1]  G. Burmester,et al.  ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany. , 2016, Rheumatology.

[2]  A. Boots,et al.  Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. , 2015, Rheumatology.

[3]  M. González-Gay,et al.  Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients. , 2015, Seminars in arthritis and rheumatism.

[4]  Thomas Breil,et al.  Multiple upper gastrointestinal perforations in a 15-year-old patient treated with tocilizumab. , 2014, Rheumatology.

[5]  C. Weyand,et al.  Giant-Cell Arteritis and Polymyalgia Rheumatica , 2003, Annals of Internal Medicine.

[6]  A. Abril,et al.  Tocilizumab, an effective treatment for relapsing giant cell arteritis. , 2014, Clinical and experimental rheumatology.

[7]  G. Herrero-Beaumont,et al.  Tocilizumab in refractory aortitis: study on 16 patients and literature review. , 2014, Clinical and experimental rheumatology.

[8]  T. Kishimoto,et al.  Longterm Safety and Effectiveness of the Anti-interleukin 6 Receptor Monoclonal Antibody Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis in Japan , 2014, The Journal of Rheumatology.

[9]  G. Baron,et al.  Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial , 2013, Annals of the rheumatic diseases.

[10]  S. Unizony,et al.  Tocilizumab for the treatment of large‐vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica , 2012, Arthritis care & research.

[11]  T. Gout,et al.  Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review , 2011, Clinical Rheumatology.

[12]  C. Spettell,et al.  The incidence of gastrointestinal perforations among rheumatoid arthritis patients. , 2011, Arthritis and rheumatism.

[13]  S. Reichenbach,et al.  Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. , 2011, Swiss medical weekly.

[14]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. , 2010, Arthritis and rheumatism.

[15]  N. Miyasaka,et al.  Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study , 2008, Annals of the rheumatic diseases.

[16]  P. Merkel,et al.  Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. , 2007, Arthritis and rheumatism.

[17]  Mahboob Rahman,et al.  Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis , 2007, Annals of Internal Medicine.

[18]  Y. Ohsugi,et al.  Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. , 2005, International immunopharmacology.

[19]  D. Colomer,et al.  Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. , 2003, Rheumatology.

[20]  C. Nordborg,et al.  The epidemiology of biopsy-positive giant cell arteritis: special reference to changes in the age of the population. , 2003, Rheumatology.

[21]  G. Hunder.  Epidemiology of giant-cell arteritis. , 2002, Cleveland Clinic journal of medicine.

[22]  J. Jover,et al.  Combined Treatment of Giant-Cell Arteritis with Methotrexate and Prednisone , 2001, Annals of Internal Medicine.

[23]  M. Sonnenblick,et al.  Giant cell arteritis in Jerusalem: a 12-year epidemiological study. , 1994, British journal of rheumatology.

[24]  K. Steinsson,et al.  Giant cell arteritis in Iceland. , 1994 .

[25]  G. Hunder,et al.  Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. , 1993, Arthritis and rheumatism.

[26]  P. Tugwell,et al.  The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. , 1990, Arthritis and rheumatism.

[27]  S. Hayat.  Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis: A Randomized Trial , 2008 .

[28]  A. Portier,et al.  Production of interleukin 6 by granulomas of giant cell arteritis. , 1994, Human immunology.

[29]  K. Steinsson,et al.  Giant cell arteritis in Iceland. An epidemiologic and histopathologic analysis. , 1994, Arthritis and rheumatism.